Updates and current challenges in microRNA research for personalized medicine in ovarian cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5): E359–86. PubMed PMID: 25220842; eng.
   PubMed Web of Science ®Google Scholar
• Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Current Oncol (Toronto, Ont). 2007 Oct;14(5):195–208. PubMed PMID: 17938703; PubMed Central PMCID: PMCPmc2002482. eng.
   PubMedGoogle Scholar
• Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002 Oct;87(1):1–7. PubMed PMID: 12468335; eng.
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002 May 23;346(21): 1616–1622. PubMed PMID: 12023993; eng.
   PubMed Web of Science ®Google Scholar
• Shuster LT, Gostout BS, Grossardt BR, et al. Prophylactic oophorectomy in premenopausal women and long-term health.Menopause Int. 2008 Sep;14(3):111–116. PubMed PMID: 18714076; PubMed Central PMCID: PMCPMC2585770. eng.
   PubMedGoogle Scholar
• Menon U, Griffin M, Gentry-Maharaj A Ovarian cancer screening–current status, future directions. Gynecol Oncol. 2014 Feb;132(2):490–495. PubMed PMID: 24316306; PubMed Central PMCID: PMCPMC3991859. eng.
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Lancet Oncol. 2015 Aug;16(8):928–936. PubMed PMID: 26115797; eng.
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.Lancet Oncol. 2016 Nov;17(11):1579–1589. PubMed PMID: 27617661; eng.
   PubMed Web of Science ®Google Scholar
• Gulyaeva LF, Kushlinskiy NE Regulatory mechanisms of microRNA expression. J Transl Med. 2016 May 20;14(1):143. PubMed PMID: 27197967; PubMed Central PMCID: PMCPMC4873990. eng.
   PubMed Web of Science ®Google Scholar
• Gurtner A, Falcone E, Garibaldi F, et al. Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity.J Exp Clin Cancer Res. 2016 Mar;12(35):45. PubMed PMID: 26971015; PubMed Central PMCID: PMCPMC4789259. eng.
   Web of Science ®Google Scholar
• Kavitha N, Vijayarathna S, Jothy SL, et al. MicroRNAs: biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis. Asian Pac J Cancer Prev. 2014;15(18):7489–7497. PubMed PMID: 25292018; eng.
   PubMedGoogle Scholar
• Li X, Wu Z, Fu X, et al. A microRNA component of the neoplastic microenvironment: microregulators with far-reaching impact. Biomed Res Int. 2013;2013:762183. PubMed PMID: 23509776; PubMed Central PMCID: PMCPMC3591172. eng.
   PubMed Web of Science ®Google Scholar
• Galasso M, Sandhu SK, Volinia S MicroRNA expression signatures in solid malignancies. Cancer J (Sudbury, Mass). 2012 May–Jun;18(3):238–243. PubMed PMID: 22647360; eng.
   PubMed Web of Science ®Google Scholar
• Skates SJ, Greene MH, Buys SS, et al. Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials. Clin Cancer Res. 2017 Jan 31. PubMed PMID: 28143870; eng.
   Web of Science ®Google Scholar
• Ortiz-Munoz B, Aznar-Oroval E, Garcia Garcia A, et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.Tumour Biol. 2014 Jul;35(7):7249–7258. PubMed PMID: 24771264; eng.
   PubMed Web of Science ®Google Scholar
• Dikmen ZG, Colak A, Dogan P, et al. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer. Eur J Gynaecol Oncol. 2015;36(4):457–462. PubMed PMID: 26390703; eng.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007 Sep 15;67(18):8699–8707. PubMed PMID: 17875710; eng.
   PubMed Web of Science ®Google Scholar
• Dahiya N, Sherman-Baust CA, Wang TL, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. Plos One. 2008 Jun 18;3(6): e2436. PubMed PMID: 18560586; PubMed Central PMCID: PMCPMC2410296. eng.
   PubMed Web of Science ®Google Scholar
• Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008 May 01;14(9): 2690–2695. PubMed PMID: 18451233; eng.
   PubMed Web of Science ®Google Scholar
• Li Y, Yao L, Liu F, et al. Characterization of microRNA expression in serous ovarian carcinoma.Int J Mol Med. 2014 Aug;34(2):491–498. PubMed PMID: 24939816; eng.
   PubMed Web of Science ®Google Scholar
• Li H, Xu Y, Qiu W, et al. Tissue miR-193b as a novel biomarker for patients with ovarian cancer. Med Sci Monit. 2015 Dec 16;21:3929–3934. PubMed PMID: 26675282; PubMed Central PMCID: PMCPMC4687946. eng.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhu MJ, Ren AM, et al. A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer. Plos One. 2014; 9(5):e96472. PubMed PMID: 24816756; PubMed Central PMCID: PMCPMC4015980. eng.
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008 Jul 29;105(30):10513–10518. PubMed PMID: 18663219; PubMed Central PMCID: PMCPMC2492472. eng.
   PubMed Web of Science ®Google Scholar
• Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids–the mix of hormones and biomarkers. Nat Reviews Clin Oncology. 2011 Jun 07;8(8): 467–477. PubMed PMID: 21647195; PubMed Central PMCID: PMCPMC3423224. eng.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer.Nat Reviews Clin Oncology. 2014 Mar;11(3):145–156. PubMed PMID: 24492836; eng.
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Tonevitsky AG, Burwinkel B Extracellular miRNA: A collision of two paradigms. Trends Biochem Sci. 2016 Oct;41(10):883–892. PubMed PMID: 27597517; eng.
   PubMed Web of Science ®Google Scholar
• Taylor DD, Gercel-Taylor C MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008 Jul;110(1):13–21. PubMed PMID: 18589210; eng.
   PubMed Web of Science ®Google Scholar
• Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.Gut. 2009 Oct;58(10):1375–1381. PubMed PMID: 19201770; eng.
   PubMed Web of Science ®Google Scholar
• Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009 Jan;112(1):55–59. PubMed PMID: 18954897; eng.
   PubMed Web of Science ®Google Scholar
• Xu YZ, Xi QH, Ge WL, et al. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev. 2013;14(2):1057–1060. PubMed PMID: 23621186; eng.
   PubMedGoogle Scholar
• Suryawanshi S, Vlad AM, Lin HM, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res. 2013 Mar 01;19(5): 1213–1224. PubMed PMID: 23362326; PubMed Central PMCID: PMCPMC3596045. eng.
   PubMed Web of Science ®Google Scholar
• Kan CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer. 2012 Dec 28;12:627. PubMed PMID: 23272653; PubMed Central PMCID: PMCPMC3542279. eng.
   PubMed Web of Science ®Google Scholar
• Gao YC, Wu J MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer. Tumour Biol. 2015 Jun;36(6):4843–4850. PubMed PMID: 25636451; eng.
   PubMed Web of Science ®Google Scholar
• Zuberi M, Mir R, Das J, et al. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.Clin Transl Oncol. 2015 Oct;17(10):779–787. PubMed PMID: 26063644; eng.
   PubMed Web of Science ®Google Scholar
• Langhe R, Norris L, Saadeh FA, et al. A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett. 2015 Jan 28;356(2 Pt B): 628–636. PubMed PMID: 25451316; eng.
   PubMed Web of Science ®Google Scholar
• Meng X, Muller V, Milde-Langosch K, et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 2016 Mar 29;7(13): 16923–16935. PubMed PMID: 26943577; PubMed Central PMCID: PMCPMC4941360. eng.
   PubMed Web of Science ®Google Scholar
• Meng X, Muller V, Milde-Langosch K, et al. Circulating cell-free miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Adv Exp Med Biol. 2016;924:3–8. PubMed PMID: 27753009; eng.
   PubMed Web of Science ®Google Scholar
• Ayaz L, Cayan F, Balci S, et al. Circulating microRNA expression profiles in ovarian cancer.J Obstet Gynaecol. 2014 Oct;34(7):620–624. PubMed PMID: 24911418; eng.
   PubMedGoogle Scholar
• Chung YW, Bae HS, Song JY, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients.Int J Gynecol Cancer. 2013 May;23(4):673–679. PubMed PMID: 23542579; eng.
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. Plos One. 2013; 8(11):e77853. PubMed PMID: 24223734; PubMed Central PMCID: PMCPMC3815222. eng.
   PubMed Web of Science ®Google Scholar
• Meng X, Joosse SA, Muller V, et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer. 2015 Nov 03;113(9): 1358–1366. PubMed PMID: 26393886; PubMed Central PMCID: PMCPMC4815782. eng.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016 Jun 24;15(1): 48. PubMed PMID: 27343009; PubMed Central PMCID: PMCPMC4921011. eng.
   PubMed Web of Science ®Google Scholar
• Zavesky L, Jandakova E, Turyna R, et al. Evaluation of cell-free urine microRNAs expression for the use in diagnosis of Ovarian and endometrial Cancers. A pilot study.Pathol Oncol Res. 2015 Sep;21(4):1027–1035. PubMed PMID: 25827090; eng.
   PubMed Web of Science ®Google Scholar
• Zhou J, Gong G, Tan H, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma.Oncol Rep. 2015 Jun;33(6):2915–2923. PubMed PMID: 25962395; eng.
   PubMed Web of Science ®Google Scholar
• Katz B, Trope CG, Reich R, et al. MicroRNAs in ovarian cancer.Hum Pathol. 2015 Sep;46(9):1245–1256. PubMed PMID: 26216350; eng.
   PubMed Web of Science ®Google Scholar
• Shah PP, Hutchinson LE, Kakar SS Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer. J Ovarian Res. 2009 Aug 27;2(1):11. PubMed PMID: 19712461; PubMed Central PMCID: PMCPMC2744658. eng.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang L, Hao Q Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. Cancer Cell Int. 2013 Aug 27;13(1):86. PubMed PMID: 23978303; PubMed Central PMCID: PMCPMC3765519. eng.
   PubMed Web of Science ®Google Scholar
• Pal MK, Jaiswar SP, Dwivedi VN, et al. MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer.Cancer Biol Med. 2015 Dec;12(4):328–341. PubMed PMID: 26779370; PubMed Central PMCID: PMCPMC4706521. eng.
   PubMed Web of Science ®Google Scholar
• Hu X, Macdonald DM, Huettner PC, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.Gynecol Oncol. 2009 Sep;114(3):457–464. PubMed PMID: 19501389; eng.
   PubMed Web of Science ®Google Scholar
• Nagaraj AB, Joseph P, DiFeo A. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. Biomark Med. 2015;9(3):241–257. PubMed PMID: 25731210; eng.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353): 609–615. PubMed PMID: 21720365; PubMed Central PMCID: PMCPMC3163504. eng.
   PubMed Web of Science ®Google Scholar
• Bagnoli M, Canevari S, Califano D, et al. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol. 2016 Aug;17(8):1137–1146. PubMed PMID: 27402147; eng.
   PubMed Web of Science ®Google Scholar
• Vaksman O, Trope C, Davidson B, et al. Exosome-derived miRNAs and ovarian carcinoma progression.Carcinogenesis. 2014 Sep;35(9):2113–2120. PubMed PMID: 24925027; eng.
   PubMed Web of Science ®Google Scholar
• Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017 May ;41:139–152. PubMed PMID: 28111228; eng.
   PubMed Web of Science ®Google Scholar
• Parikh A, Lee C, Joseph P, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977. PubMed PMID: 24394555; PubMed Central PMCID: PMCPMC3896774. eng.
   PubMed Web of Science ®Google Scholar
• Kwon MJ, Shin YK Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci. 2013 Mar 25;14(4):6624–6648. PubMed PMID: 23528891; PubMed Central PMCID: PMCPMC3645658. eng.
   PubMed Web of Science ®Google Scholar
• Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res. 2008 Dec 15;68(24): 10307–10314. PubMed PMID: 19074899; PubMed Central PMCID: PMCPMC2762326. eng.
   PubMed Web of Science ®Google Scholar
• Wendler A, Keller D, Albrecht C, et al. Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cells. Oncol Rep. 2011 Jan;25(1):273–279. PubMed PMID: 21109987; eng.
   PubMed Web of Science ®Google Scholar
• Hampton KK, Stewart R, Napier D, et al. PGRMC1 elevation in multiple cancers and essential role in stem cell survival.Advances Lung Cancer (Irvine). 2015 Sep;4(3):37–51. PubMed PMID: 27867772; PubMed Central PMCID: PMCPMC5113835. eng.
   PubMedGoogle Scholar
• Liu Z, Gersbach E, Zhang X, et al. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.Mol Cancer Res. 2013 Nov;11(11):1314–1325. PubMed PMID: 24045973; PubMed Central PMCID: PMCPMC3911890. eng.
   PubMed Web of Science ®Google Scholar
• Vecchione A, Belletti B, Lovat F, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA. 2013 Jun 11;110(24): 9845–9850. PubMed PMID: 23697367; PubMed Central PMCID: PMCPMC3683704. eng.
   PubMed Web of Science ®Google Scholar
• Olson TA, Murray MJ, Rodriguez-Galindo C, et al. Pediatric and adolescent extracranial germ cell tumors: the road to collaboration. J Clin Oncol. 2015 Sep 20;33(27): 3018–3028. PubMed PMID: 26304902; PubMed Central PMCID: PMCPmc4979195. eng.
   PubMed Web of Science ®Google Scholar
• Liu G, Yang D, Rupaimoole R, et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst. 107(7) Jul 2015:1-12. PubMed PMID: 25995442; PubMed Central PMCID: PMCPMC4554255. eng.
   Google Scholar
• Choi YE, Meghani K, Brault ME, et al. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer. Cell Rep. 2016 Jan 26;14(3): 429–439. PubMed PMID: 26774475; PubMed Central PMCID: PMCPMC4731274. eng.
   PubMed Web of Science ®Google Scholar
• Kapetanakis NI, Uzan C, Jimenez-Pailhes AS, et al. Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival. Oncotarget. 2015 Nov 03;6(34): 36815–36824. PubMed PMID: 26416421; PubMed Central PMCID: PMCPMC4742212. eng.
   PubMed Web of Science ®Google Scholar
• Benson EA, Skaar TC, Liu Y, et al. Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: a pilot study. Plos One. 2015; 10(10):e0141279. PubMed PMID: 26485143; PubMed Central PMCID: PMCPMC4612782. eng.
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies.Cancer Prev Res (Philadelphia, Pa). 2012 Mar;5(3):492–497. PubMed PMID: 22158052; PubMed Central PMCID: PMCPMC4186243. eng.
   PubMed Web of Science ®Google Scholar
• Liu J, Matulonis UA New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res. 2014 Oct 15;20(20):5150–5156. PubMed PMID: 25320365; eng.
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang L, Huang H, et al. MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4. Oncotarget. 2015 Sep 15;6(27): 23793–23806. PubMed PMID: 26204489; PubMed Central PMCID: PMCPMC4695152. eng.
   PubMed Web of Science ®Google Scholar
• Teng Y, Zhang Y, Qu K, et al. MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3. Oncotarget. 2015 Dec 01;6(38): 40799–40814. PubMed PMID: 26512921; PubMed Central PMCID: PMCPMC4747369. eng.
   PubMed Web of Science ®Google Scholar
• Sestito R, Cianfrocca R, Rosano L, et al. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget. 2016 Jan 26;7(4): 4009–4023. PubMed PMID: 26675258; PubMed Central PMCID: PMCPMC4826186. eng.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen S, Xiu YL, et al. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression. Mol Cancer. 2015 Feb 04;14:31. PubMed PMID: 25649143; PubMed Central PMCID: PMCPMC4328068. eng.
   PubMed Web of Science ®Google Scholar
• Chen S, Chen X, Xiu YL, et al. Inhibition of ovarian epithelial carcinoma tumorigenesis and progression by microRNA 106b mediated through the RhoC pathway. Plos One. 2015; 10(5):e0125714. PubMed PMID: 25933027; PubMed Central PMCID: PMCPMC4416747. eng.
   PubMed Web of Science ®Google Scholar
• Ying X, Wei K, Lin Z, et al. MicroRNA-125b suppresses ovarian cancer progression via suppression of the epithelial-mesenchymal transition pathway by targeting the SET protein. Cell Physiol Biochem. 2016; 39(2):501–510. PubMed PMID: 27383536; eng.
   PubMed Web of Science ®Google Scholar
• Guo J, Xia B, Meng F, et al. miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor.Tumour Biol. 2014 Feb;35(2):1557–1564. PubMed PMID: 24127040; eng.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Z, Gai F, et al. MicroRNA-137 suppresses tumor growth in epithelial ovarian cancer in vitro and in vivo.Mol Med Rep. 2015 Aug;12(2):3107–3114. PubMed PMID: 25955305; eng.
   PubMed Web of Science ®Google Scholar
• Dong R, Liu X, Zhang Q, et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget. 2014 Nov 15;5(21): 10816–10829. PubMed PMID: 25333261; PubMed Central PMCID: PMCPMC4279412. eng.
   PubMed Web of Science ®Google Scholar
• Chen X, Dong C, Law PT, et al. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.Gynecol Oncol. 2015 Dec;139(3):513–519. PubMed PMID: 26472353; eng.
   PubMed Web of Science ®Google Scholar
• Wu SY, Rupaimoole R, Shen F, et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat Commun. 2016 Apr 04;7:11169. PubMed PMID: 27041221; PubMed Central PMCID: PMCPMC4822037. eng.
   PubMed Web of Science ®Google Scholar
• Mitra AK, Chiang CY, Tiwari P, et al. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. 2015 Nov 26;34(48): 5923–5932. PubMed PMID: 25798837; PubMed Central PMCID: PMCPMC4580483. eng.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhang Y, Wang J, et al. MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res. 2013 Jul 10;6(1): 50. PubMed PMID: 23842108; PubMed Central PMCID: PMCPMC3729499. eng.
   PubMed Web of Science ®Google Scholar
• Ge T, Yin M, Yang M, et al. MicroRNA-302b suppresses human epithelial ovarian cancer cell growth by targeting RUNX1. Cell Physiol Biochem. 2014; 34(6):2209–2220. PubMed PMID: 25562167; eng.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao FJ, Chen LL, et al. MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget. 2014 Dec 15;5(23): 12291–12303. PubMed PMID: 25460499; PubMed Central PMCID: PMCPMC4323008. eng.
   PubMed Web of Science ®Google Scholar
• Chen S, Chen X, Xiu YL, et al. MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression. Cancer Lett. 2015 Jun 28;362(1): 122–130. PubMed PMID: 25819031; eng.
   PubMed Web of Science ®Google Scholar
• Leng R, Zha L, Tang L MiR-718 represses VEGF and inhibits ovarian cancer cell progression. FEBS Lett. 2014 Jun 05;588(12):2078–2086. PubMed PMID: 24815691; eng.
   PubMed Web of Science ®Google Scholar
• Kanlikilicer P, Rashed MH, Bayraktar R, et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res. 2016 Dec 15;76(24): 7194–7207. can-16-0714. PubMed PMID: 27742688; eng.
   PubMed Web of Science ®Google Scholar
• Dwivedi SK, Mustafi SB, Mangala LS, et al. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22;7(12): 15093–15104. PubMed PMID: 26918603; PubMed Central PMCID: PMCPMC4924772. eng.
   PubMed Web of Science ®Google Scholar
• Seviour EG, Sehgal V, Lu Y, et al. Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene. 2016 Feb 11;35(6): 691–701. PubMed PMID: 25639871; PubMed Central PMCID: PMCPMC4522411. eng.
   PubMed Web of Science ®Google Scholar
• Zhu X, Li Y, Xie C, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014 Sep 15;135(6): 1286–1296. PubMed PMID: 24510775; eng.
   PubMed Web of Science ®Google Scholar
• Zhu X, Shen H, Yin X, et al. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene. 2016 Jan 21;35(3): 323–332. PubMed PMID: 25867064; eng.
   PubMed Web of Science ®Google Scholar
• Xu S, Fu GB, Tao Z, et al. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget. 2015 Sep 22;6(28): 26457–26471. PubMed PMID: 26238185; PubMed Central PMCID: PMCPMC4694914. eng.
   PubMed Web of Science ®Google Scholar
• Wu DD, Li XS, Meng XN, et al. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.Tumour Biol. 2016 Aug;37(8):10499–10506. PubMed PMID: 26850595; eng.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang L, Zhang L, et al. MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner. Am J Transl Res. 2016;8(4):1748–1755. PubMed PMID: 27186298; PubMed Central PMCID: PMCPMC4859903. eng.
   PubMed Web of Science ®Google Scholar
• Yang L, Wei QM, Zhang XW, et al. MiR-376a promotion of proliferation and metastases in ovarian cancer: potential role as a biomarker. Life Sci. 2017 Mar 15;173:62–67. PubMed PMID: 27979415; eng.
   PubMed Web of Science ®Google Scholar
• Liu J, Dou Y, Sheng M Inhibition of microRNA-383 has tumor suppressive effect in human epithelial ovarian cancer through the action on caspase-2 gene. Biomed Pharmacother. 2016 Oct;83:1286–1294. PubMed PMID: 27567588; eng.
   PubMed Web of Science ®Google Scholar
• Chaluvally-Raghavan P, Jeong KJ, Pradeep S, et al. Direct upregulation of STAT3 by MicroRNA-551b-3p deregulates growth and metastasis of ovarian cancer. Cell Rep. 2016 May 17;15(7): 1493–1504. PubMed PMID: 27160903; PubMed Central PMCID: PMCPMC4914391. eng.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu J, Zang D, et al. Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression. Oncotarget. 2015 Jun 20;6(17): 15180–15193. PubMed PMID: 25893382; PubMed Central PMCID: PMCPMC4558144. eng.
   PubMed Web of Science ®Google Scholar
• Wu G, Liu A, Zhu J, et al. MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/beta-catenin signaling pathway. Oncotarget. 2015 Oct 6;06(30): 28882–28894. PubMed PMID: 26337084; PubMed Central PMCID: PMCPMC4745698. eng.
   Google Scholar
• Wei Z, Liu Y, Wang Y, et al. Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer.Med Oncol. 2016 Nov;33(11):126. PubMed PMID: 27743201; PubMed Central PMCID: PMCPMC5065596. eng.
   PubMed Web of Science ®Google Scholar
• Chen WT, Yang YJ, Zhang ZD, et al. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression. J Ovarian Res. 2017 Jan 11;10(1): 1. PubMed PMID: 28086946; PubMed Central PMCID: PMCPMC5234104. eng.
   PubMed Web of Science ®Google Scholar
• Garofalo M, Leva GD, Croce CM, MicroRNAs as anti-cancer therapy. Curr Pharm Des. 2014;2033:5328–5335. PubMed PMID: 24479801; eng.
   PubMed Web of Science ®Google Scholar
• Chang H, Yi B, Ma R, et al. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Sci Rep. 2016 Feb 29;6:22312. PubMed PMID: 26924382; PubMed Central PMCID: PMCPMC4770416. eng.
   PubMed Web of Science ®Google Scholar
• Belter A, Rolle K, Piwecka M, et al. Inhibition of miR-21 in glioma cells using catalytic nucleic acids. Sci Rep. 2016 Apr 15;6:24516. PubMed PMID: 27079911; PubMed Central PMCID: PMCPMC4832220. eng.
   PubMed Web of Science ®Google Scholar
• van ser Ree MH, Van Der Meer AJ, de Bruijne J. et al., Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res. 2014 Nov;111:53–59. PubMed PMID: 25218783; eng.
   PubMed Web of Science ®Google Scholar
• van der Ree MH, van der Meer AJ, van Nuenen AC, et al. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.Aliment Pharmacol Ther. 2016 Jan;43(1):102–113. PubMed PMID: 26503793; eng.
   PubMed Web of Science ®Google Scholar
• Hong DS, Kang Y-K, Brenner AJ, et al. MRX34, a liposomal miR-34 mimic, in patients with advanced solid tumors: final dose-escalation results from a first-in-human phase I trial of microRNA therapy. J Clin Oncol. 2016;34(suppl; abstr 2508):2508.
   Google Scholar
• Querfeld C, Pacheco T, Foss FM, et al. Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA antimiR) of microRNA-155, in Patients with CTCL. Blood. 2016;128(22):1829–1829.
   PubMed Web of Science ®Google Scholar
• Reid G, Kao SC, Pavlakis N, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer.Epigenomics. 2016 Aug;8(8):1079–1085. PubMed PMID: 27185582; eng.
   PubMed Web of Science ®Google Scholar
• Li XJ, Ren ZJ, Tang JH. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 2014 Jul 17; 5: e1327. PubMed PMID: 25032850; PubMed Central PMCID: PMCPMC4123066. eng.
   PubMed Web of Science ®Google Scholar
• Corney DC, Hwang CI, Matoso A, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010 Feb 15;16(4): 1119–1128. PubMed PMID: 20145172; PubMed Central PMCID: PMCPMC2822884. eng.
   PubMed Web of Science ®Google Scholar
• Business Wire [Internet]. Austin (TX). http://www.businesswire.com BWMTHPCSoMScSAfh.
   Google Scholar
• MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics.Cancer Cell. 2007 May;11(5):431–445. PubMed PMID: 17482133; eng.
   PubMed Web of Science ®Google Scholar
• Patrono MG, Iniesta MD, Malpica A, et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review.Gynecol Oncol. 2015 Dec;139(3):568–572. PubMed PMID: 26407480; eng.
   PubMed Web of Science ®Google Scholar
• Koshiyama M, Matsumura N, Konishi I. Subtypes of ovarian cancer and ovarian cancer screening. Diagnostics (Basel, Switzerland). 2017 Mar 02;7(1). PubMed PMID: 28257098; PubMed Central PMCID: PMCPMC5373021. eng. DOI: 10.3390/diagnostics7010012
   PubMedGoogle Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 01;375(22): 2154–2164. PubMed PMID: 27717299; eng.
   PubMed Web of Science ®Google Scholar
• Mateescu B, Batista L, Cardon M, et al. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med. 2011 Nov 20;17(12): 1627–1635. PubMed PMID: 22101765; eng.
   PubMed Web of Science ®Google Scholar
• Meryet-Figuiere M, Lambert B, Gauduchon P, et al. An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016 Jul 12;7(28): 44719–44734. PubMed PMID: 26992233; PubMed Central PMCID: PMCPMC5190131. eng.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Da Silva AM, Calin G, et al. Data normalization strategies for MicroRNA quantification.Clin Chem. 2015 Nov;61(11):1333–1342. PubMed PMID: 26408530; PubMed Central PMCID: PMCPMC4890630. eng.
   PubMed Web of Science ®Google Scholar
• Witwer KW, Halushka MK Toward the promise of microRNAs - Enhancing reproducibility and rigor in microRNA research. RNA Biol. 2016 Nov;13(11):1103–1116. PubMed PMID: 27645402; eng.
   PubMed Web of Science ®Google Scholar
• Vigneron N, Meryet-Figuiere M, Guttin A, et al. Towards a new standardized method for circulating miRNAs profiling in clinical studies: interest of the exogenous normalization to improve miRNA signature accuracy.Mol Oncol. 2016 Aug;10(7):981–992. PubMed PMID: 27083764; eng.
   PubMed Web of Science ®Google Scholar
• Banzhaf-Strathmann J, Edbauer D Good guy or bad guy: the opposing roles of microRNA 125b in cancer. Cell Commun Signal. 2014 Apr;28(12):30. PubMed PMID: 24774301; PubMed Central PMCID: PMCPMC4011766. eng.
   Web of Science ®Google Scholar
• Wang H, Jiang Y, Peng H. et al., Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Adv Drug Deliv Rev. 2015 Jan;81:142–160. PubMed PMID: 25450259; eng.
   PubMed Web of Science ®Google Scholar
• miRNAs as tools for tailoring personalized therapeutic strategies in ovarian carcinoma. RNA Dis. 2015. DOI: 10.14800/rd.717
   Google Scholar
• Denoyelle C, Lambert B, Meryet-Figuiere M, et al. miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis. 2014 Oct 09;5:e1445. PubMed PMID: 25299770; PubMed Central PMCID: PMCPMC4649504. eng.
   PubMed Web of Science ®Google Scholar